Molecular Oncology Program
Molecular Oncology Program
批准号:
10712671
负责人:
Pamela N. Munster
金额:
$18.52万
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
未结题
起止时间:
1999-08-05 至 2028-05-31
关键词:
BackBasic ScienceBehaviorBig Data MethodsBiological MarkersBiologyCancer Center Support GrantChemicalsChromosome MappingClinicalComputersDiagnosticDisciplineDissemination and ImplementationDrug TargetingDrug resistanceEarly DiagnosisEnvironmentEpidemiologistEpigenetic ProcessFoundationsGeneticGoalsIncidenceKRAS2 geneMalignant NeoplasmsMissionMutationPathway interactionsPhenotypePopulation HeterogeneityPredispositionPreventiveResearchResearch PersonnelResistance developmentResourcesRiskRisk FactorsScientistSignal PathwaySystems BiologyTechnologyTherapeuticTissuesTraining and EducationTranslatingTranslationsTumor BiologyWorkanticancer researchbench to bedsideclinical applicationcollaborative environmentcommunity engagementimaging detectionmembermolecular oncologymutantnew therapeutic targetnovelnovel therapeuticsoncology programprogramstooltreatment responsetumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Molecular Oncology Program: Summary/Abstract
The goal of the HDFCCC Molecular Oncology Program (MO) is to discover, develop, and translate novel
preventive and therapeutic strategies and biomarkers. This is done through research that spans from basic
science at the bench and computer to clinical applications and back, and by focusing on bridging the gap
between scientists and clinical researchers, and from bench to start-up company to bedside. All MO Program
activities reflect the HDFCCC’s cross-cutting themes of Impactful Discovery (Theme 1), Effective Translation
(Theme 2), and Implementation and Dissemination (Theme 3) and are bolstered by the resources and
collaborative environment provided by the HDFCCC. MO is a new research program since the prior competing
renewal. The Center-wide realignment of research programs now allows MO members to interact around
diagnostics and therapies focused on signaling pathways and epigenetics, as well as on therapies that are
mutation-directed but tissue-agnostic, thus spanning multiple disciplines and connecting clinicians,
epidemiologists, and basic scientists. Specifically, MO member research focuses on (1) studying the impact of
genetics on cancer susceptibility, progression, and therapeutic response; (2) modulating signaling pathways for
therapeutic benefit; and (3) developing tools and technologies to dissect tumor and host environment networks.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Integrating Epigenetic Modulation into DNA Damage Repair
-
批准号:10446970
-
项目类别:
-
资助金额:$65.69万
-
财政年份:2022
-
负责人:Pamela N. Munster
-
依托单位:
Integrating Epigenetic Modulation into DNA Damage Repair
-
批准号:10632128
-
项目类别:
-
资助金额:$64.29万
-
财政年份:2022
-
负责人:Pamela N. Munster
-
依托单位:
Developing silastic-silicone for the local delivery of hormonal therapy to prevent and treat breast cancer
-
批准号:10180911
-
项目类别:
-
资助金额:$36.26万
-
财政年份:2017
-
负责人:Pamela N. Munster
-
依托单位:
Developing silastic-silicone for the local delivery of hormonal therapy to prevent and treat breast cancer
-
批准号:9368775
-
项目类别:
-
资助金额:$36.26万
-
财政年份:2017
-
负责人:Pamela N. Munster
-
依托单位:
The role of HDAC2 in hormone therapy resistance
-
批准号:8517452
-
项目类别:
-
资助金额:$30.14万
-
财政年份:2011
-
负责人:Pamela N. Munster
-
依托单位:
The role of HDAC2 in hormone therapy resistance
-
批准号:8891377
-
项目类别:
-
资助金额:$32.06万
-
财政年份:2011
-
负责人:Pamela N. Munster
-
依托单位:
The role of HDAC2 in hormone therapy resistance
-
批准号:8705456
-
项目类别:
-
资助金额:$31.1万
-
财政年份:2011
-
负责人:Pamela N. Munster
-
依托单位:
The role of HDAC2 in hormone therapy resistance
-
批准号:8073790
-
项目类别:
-
资助金额:$32.06万
-
财政年份:2011
-
负责人:Pamela N. Munster
-
依托单位:
The Role of Selective HDAC Enzymes in Drug Sensitivity
-
批准号:7674687
-
项目类别:
-
资助金额:$27.16万
-
财政年份:2007
-
负责人:Pamela N. Munster
-
依托单位:
The Role of Selective HDAC Enzymes in Drug Sensitivity
-
批准号:7425302
-
项目类别:
-
资助金额:$27.16万
-
财政年份:2007
-
负责人:Pamela N. Munster
-
依托单位:
The Role of Selective HDAC Enzymes in Drug Sensitivity
-
批准号:7265531
-
项目类别:
-
资助金额:$29.29万
-
财政年份:2007
-
负责人:Pamela N. Munster
-
依托单位:
The Role of Selective HDAC Enzymes in Drug Sensitivity
-
批准号:7883605
-
项目类别:
-
资助金额:$27.16万
-
财政年份:2007
-
负责人:Pamela N. Munster
-
依托单位:
Potentiation of Topo Inhibitors by the HDACi, SAHA
-
批准号:7058377
-
项目类别:
-
资助金额:$21.64万
-
财政年份:2006
-
负责人:Pamela N. Munster
-
依托单位:
Potentiation of Topo Inhibitors by the HDACi, SAHA
-
批准号:7230027
-
项目类别:
-
资助金额:$21.02万
-
财政年份:2006
-
负责人:Pamela N. Munster
-
依托单位:
Potentiation of Topo Inhibitors by HDAC Inhibitors
-
批准号:6835256
-
项目类别:
-
资助金额:$25.22万
-
财政年份:2004
-
负责人:Pamela N. Munster
-
依托单位:
Potentiation of Topo Inhibitors by HDAC Inhibitors
-
批准号:6952819
-
项目类别:
-
资助金额:$25.22万
-
财政年份:2004
-
负责人:Pamela N. Munster
-
依托单位:
Molecular Oncology Program
-
批准号:10406950
-
项目类别:
-
资助金额:$8.73万
-
财政年份:1999
-
负责人:Pamela N. Munster
-
依托单位:
Experimental Therapeutics Program
-
批准号:9570986
-
项目类别:
-
资助金额:$8.65万
-
财政年份:--
-
负责人:Pamela N. Munster
-
依托单位:
海外基金